A cancer tumor is a veritable patchwork of cells with a variety of genetic fingerprints.
Immunitas Therapeutics is using single-cell genomics—an approach that studies the genetic activity of individual cells—to peer deeply into patient tumors and more precisely determine what is fueling the growth.
With that knowledge, the company plans to develop new targets for treating forms of the disease based on what it learns about the interactions between immune cells and cancer cells around tumors.
Now the Boston company has raised $39 million to advance compounds discovered with its computational platform into human testing by the end of 2022.
The… Read more »
UNDERWRITERS AND PARTNERS
